COMP <GO>
TDOC vs ABBV // NET PROFIT MARGIN
Teladoc Health Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: TDOC 4
— ABBV 9
▲ NET PROFIT MARGIN LEADER: ABBV
LAST: $8.51 (-2.52%) • MKT CAP: $1.59B
net-margins
-7.90%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
net-margins
6.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TDOC VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TDOC | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -17.00% | 29.00% | -46.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 18.00% | 3.47% | +14.53 | TDOC | /fcf-yield <GO> |
| Operating Margin | -10.40% | 24.60% | -35.00 | ABBV | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -7.90% | 6.90% | -14.80 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | -1.50% | 8.60% | -10.10 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 5.33 | -4.88 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.40% | -0.20 | TDOC | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 77.7 | 72.8 | +4.91 | TDOC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.15 | -0.07 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | 113.1x | -81.10 | TDOC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.59B | $513.86B | -$512.27B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TDOC REV | ABBV REV | TDOC GROSS % | ABBV GROSS % | TDOC FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.53B | $61.16B | 44.0% | 70.2% | $285.5M | $17.82B |
| FY 2024 | $2.57B | $56.33B | 44.0% | 70.0% | $282.9M | $17.83B |
| FY 2023 | $2.60B | $54.32B | 44.0% | 44.0% | $232.9M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TDOC // BETA 1.08
ABBV // BETA 1.15